The National Institute for Health and Care Excellence10h
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...
National Institute for Health and Care Excellence4d
2 Information about blinatumomab
Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...
National Institute for Health and Care Excellence6d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and over. It is ...
National Institute for Health and Care Excellence6d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
There is a simple discount patient access scheme for fenfluramine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence6d
Information for the public
Lisocabtagene maraleucel (liso‑cel; Breyanzi) is available on the NHS. It is a possible treatment for large B-cell lymphoma (diffuse large B‑cell, high-grade B‑cell, primary mediastinal large B-cell ...
National Institute for Health and Care Excellence6d
5 Evaluation committee members and NICE project team
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence6d
2 Information about lisocabtagene maraleucel
Lisocabtagene maraleucel (liso‑cel; Breyanzi, Bristol-Myers Squibb) is indicated for 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL), high grade B‑cell lymphoma (HGBCL), ...
National Institute for Health and Care Excellence6d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age ...
National Institute for Health and Care Excellence6d
5 Evaluation committee members and NICE project team
This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee. The highly specialised technologies evaluation committee and the 4 technology ...
National Institute for Health and Care Excellence6d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence6d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence6d
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...